WCLC 2025 - Posters & ePosters-EP.17.26 Survival in Advanced NSCLC Patients With PD-L1 =50% Treated With ICIs : A Multicenter, Retrospective Real-World Study in Georgia

EP.17.26 Survival in Advanced NSCLC Patients With PD-L1 =50% Treated With ICIs : A Multicenter, Retrospective Real-World Study in Georgia

Back to course

Pdf Summary

This multicenter retrospective study in Georgia evaluated the real-world efficacy and survival outcomes of advanced non-small cell lung cancer (aNSCLC) patients with high PD-L1 expression (≥50%) treated with immune checkpoint inhibitors (ICIs), primarily pembrolizumab. The study included 49 aNSCLC patients without driver mutations, mostly male (93%) with a median age of 69 years, and predominantly stage IV disease (88%). Histology was nearly evenly split between squamous (47%) and non-squamous carcinoma (53%). Patients received ICIs mostly as first-line therapy (84%) with a median of 7 treatment cycles and a median follow-up of 16 months.<br /><br />Key outcomes showed a median progression-free survival (PFS) of 10 months and an overall survival (OS) of 22 months, aligning closely with results from clinical trials, although PFS was somewhat shorter. The best treatment responses included partial response in 46% of patients, stable disease in 24%, and disease progression in 24%. Adverse events were common, reported in 70% of patients, with 35% experiencing grade 2-3 toxicities. Notably, two patients died from immune-related adverse events.<br /><br />The study concludes that monotherapy with ICIs is effective in treating aNSCLC patients with high PD-L1 in a real-world setting, with OS benefits consistent with clinical trial data, despite slightly lower PFS. Limitations include its retrospective design and relatively small sample size. Future research could further clarify these findings and optimize treatment strategies for this patient population in routine clinical practice.

Asset Subtitle

Ana Tsereteli

Meta Tag

Speaker Ana Tsereteli

Topic Global Health, Health Services, and Health Economics

Keywords

advanced non-small cell lung cancer

aNSCLC

high PD-L1 expression

immune checkpoint inhibitors

pembrolizumab

real-world study

progression-free survival

overall survival

treatment response

immune-related adverse events